Cargando…
Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT): A Strobe-compliant observational study
Percutaneous microwave ablation therapy (PMCT) has been recommended for elderly hepatocellular carcinoma (HCC) patients who cannot tolerate surgery due to their age or presence of comorbidities. Few studies have investigated efficacy and treatment outcomes for PMCT treatment in these patients, espec...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393083/ https://www.ncbi.nlm.nih.gov/pubmed/30170369 http://dx.doi.org/10.1097/MD.0000000000011618 |
_version_ | 1783398622049599488 |
---|---|
author | Shen, Xiaozhang Ma, Sicong Tang, Xiaoyin Wang, Tao Qi, Xingxing Chi, Jiachang Wang, Zhi Cui, Dan Zhang, Yuan Li, Ping Zhai, Bo |
author_facet | Shen, Xiaozhang Ma, Sicong Tang, Xiaoyin Wang, Tao Qi, Xingxing Chi, Jiachang Wang, Zhi Cui, Dan Zhang, Yuan Li, Ping Zhai, Bo |
author_sort | Shen, Xiaozhang |
collection | PubMed |
description | Percutaneous microwave ablation therapy (PMCT) has been recommended for elderly hepatocellular carcinoma (HCC) patients who cannot tolerate surgery due to their age or presence of comorbidities. Few studies have investigated efficacy and treatment outcomes for PMCT treatment in these patients, especially in China, where patients are more often diagnosed and treated early in life. This study evaluated the safety and efficacy of ultrasound-guided PMCT in treatment-naive elderly HCC patients, and analyzed risk factors associated with poor treatment outcomes. The 65 HCC patients in this retrospective study were divided into 2 groups: <65 years old or ≥65 years old. Patients received PMCT every month until tumor was unobservable and were then followed for 1 month after ablation. The primary clinical endpoint was the rate of complete tumor ablation, and secondary endpoints were progression-free survival and overall survival. Patients ≥65 years old had significantly poorer performance status than younger patients, but similar rates of complete ablation. Multiple tumors and hypertension were associated with a significantly higher risk of death, while higher postoperative alanine aminotransferase levels were associated with a significantly lower risk of death. Patients with tumor sizes >5 to ≤ 10 cm were at a significantly higher risk for disease progression than patients with tumor sizes >1 to ≤ 3 cm. Complete ablation significantly lowered the risk of disease progression. PMCT is safe and effective for patients ≥65 years of age, achieving total ablation in more than 90% of patients. Age and comorbidities did not affect clinical outcome. |
format | Online Article Text |
id | pubmed-6393083 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-63930832019-03-15 Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT): A Strobe-compliant observational study Shen, Xiaozhang Ma, Sicong Tang, Xiaoyin Wang, Tao Qi, Xingxing Chi, Jiachang Wang, Zhi Cui, Dan Zhang, Yuan Li, Ping Zhai, Bo Medicine (Baltimore) Research Article Percutaneous microwave ablation therapy (PMCT) has been recommended for elderly hepatocellular carcinoma (HCC) patients who cannot tolerate surgery due to their age or presence of comorbidities. Few studies have investigated efficacy and treatment outcomes for PMCT treatment in these patients, especially in China, where patients are more often diagnosed and treated early in life. This study evaluated the safety and efficacy of ultrasound-guided PMCT in treatment-naive elderly HCC patients, and analyzed risk factors associated with poor treatment outcomes. The 65 HCC patients in this retrospective study were divided into 2 groups: <65 years old or ≥65 years old. Patients received PMCT every month until tumor was unobservable and were then followed for 1 month after ablation. The primary clinical endpoint was the rate of complete tumor ablation, and secondary endpoints were progression-free survival and overall survival. Patients ≥65 years old had significantly poorer performance status than younger patients, but similar rates of complete ablation. Multiple tumors and hypertension were associated with a significantly higher risk of death, while higher postoperative alanine aminotransferase levels were associated with a significantly lower risk of death. Patients with tumor sizes >5 to ≤ 10 cm were at a significantly higher risk for disease progression than patients with tumor sizes >1 to ≤ 3 cm. Complete ablation significantly lowered the risk of disease progression. PMCT is safe and effective for patients ≥65 years of age, achieving total ablation in more than 90% of patients. Age and comorbidities did not affect clinical outcome. Wolters Kluwer Health 2018-08-21 /pmc/articles/PMC6393083/ /pubmed/30170369 http://dx.doi.org/10.1097/MD.0000000000011618 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | Research Article Shen, Xiaozhang Ma, Sicong Tang, Xiaoyin Wang, Tao Qi, Xingxing Chi, Jiachang Wang, Zhi Cui, Dan Zhang, Yuan Li, Ping Zhai, Bo Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT): A Strobe-compliant observational study |
title | Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT): A Strobe-compliant observational study |
title_full | Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT): A Strobe-compliant observational study |
title_fullStr | Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT): A Strobe-compliant observational study |
title_full_unstemmed | Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT): A Strobe-compliant observational study |
title_short | Clinical outcome in elderly Chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (PMCT): A Strobe-compliant observational study |
title_sort | clinical outcome in elderly chinese patients with primary hepatocellular carcinoma treated with percutaneous microwave coagulation therapy (pmct): a strobe-compliant observational study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393083/ https://www.ncbi.nlm.nih.gov/pubmed/30170369 http://dx.doi.org/10.1097/MD.0000000000011618 |
work_keys_str_mv | AT shenxiaozhang clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy AT masicong clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy AT tangxiaoyin clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy AT wangtao clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy AT qixingxing clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy AT chijiachang clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy AT wangzhi clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy AT cuidan clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy AT zhangyuan clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy AT liping clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy AT zhaibo clinicaloutcomeinelderlychinesepatientswithprimaryhepatocellularcarcinomatreatedwithpercutaneousmicrowavecoagulationtherapypmctastrobecompliantobservationalstudy |